Empasug-LG 25mg

Description:

• Empasug-LG 25mg is a fixed-dose oral antihyperglycemic agent combining empagliflozin (25 mg) and linagliptin (5 mg). This dual-mechanism tablet is indicated for adults with type 2 diabetes mellitus (T2DM) to improve glycemic control. The combination leverages SGLT2 inhibition to promote urinary glucose excretion and DPP-4 inhibition to enhance insulin secretion and suppress glucagon. It is not indicated for type 1 diabetes or diabetic ketoacidosis.
• As one of the trusted choices among empagliflozin tablet manufacturers, this formulation ensures consistent quality and clinical effectiveness.

Key Features:

• Combines empagliflozin and linagliptin for complementary glycemic control

• Supports HbA1c reduction and improved postprandial glucose regulation

• Demonstrates cardiovascular and renal protection in clinical settings

• Provides a once-daily oral dosing schedule to improve patient compliance

• Well-suited for patients requiring dual antihyperglycemic therapy

• Widely recommended by diabetes medicine wholesalers due to its effective dual-action mechanism

Usage Guidelines:

• Take once daily, with or without food

• Initiate therapy in adults not adequately controlled on monotherapy

• Monitor renal function and glycemic response during use

Safety Profile:

• Side effects may include nasopharyngitis, urinary tract infections, or headaches

• Avoid in patients with eGFR <30 mL/min/1.73m², type 1 diabetes, or ketoacidosis

• Monitor for ketoacidosis, hypovolemia, and signs of pancreatitis

Uses / Indications: Used in adults with type 2 diabetes mellitus (T2DM) to improve blood sugar control as an adjunct to diet and exercise. This combination of SGLT2 inhibitor (Empagliflozin) and DPP-4 inhibitor (Linagliptin) provides dual glucose-lowering effects. Not for type 1 diabetes or diabetic ketoacidosis.